Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8603ee14f13e9c3d3f6d5858bf4f3bf |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57563 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
filingDate |
2007-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7704bb66ba28a8bf417b45d4cb3fae6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2210a7bf54a7d6d7961f01bdbc08a9ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27e77bd0fbd0b64ed123d58655ff4661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_150b2e87cb3ab94333b1701ed5359569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7dce7890603626b9e9e3aa972627d54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5de70698f05112ccb686ace85564eddc |
publicationDate |
2009-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2009019027-A |
titleOfInvention |
Insulin-secreting peptide derivatives with amino-terminal amino acid mutations |
abstract |
The present invention provides an insulinotropic peptide having a high activity by mutating the amino terminal amino acid of the insulinotropic peptide, and a pharmaceutical composition containing the same. Insulin secretory peptide derivatives exhibiting therapeutic effects not exhibited by other natural and conventional insulin secretory peptide analogs. The insulin secretory peptide derivative and a pharmaceutical composition containing the insulin secretory peptide derivative can be used to effectively treat the above-mentioned diseases that could not be predicted in the past. [Selection figure] None |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013537525-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016504379-A |
priorityDate |
2007-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |